biostudies-literatureBoan JInstituto de Salud Carlos III (ISCIII), Spanish Ministry of Science, Innovation and Universities.e70163https://www.ebi.ac.uk/biostudies/studies/S-EPMC12922572biostudies-literatureUnknown69(2)<h4>Background</h4>Echinocandins are the first-line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once-weekly intravenous administration, offering potential advantages in complex clinical settings.<h4>Objectives</h4>We aimed to describe our real-world experience with rezafungin for the treatment of invasive fungal disease (IFD).<h4>Patients</h4>A retrospective analysis of consecutive patients treated with rezafungin for proven IFD at our center between September 2022 and December 2025 was conducted.<h4>Results</h4>We included 13 patients (mean age: 59.4 ± 17.8 years). Main predisposing conditions included immunosuppression (53.8% [solid organ transplantation in 30.8%]), solid cancer (30.8%) and recent surgicalMycosesRezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real-World Clinical Practice.PMC12922572CM25/00250CM25/00243JR24/00034Perez-Ayala APerez-Jacoiste Asin MACaro-Teller JMAguado JMSan-Juan RLopez-Medrano FBoan JFernandez-Ruiz MRodriguez-Goncer IAparicio-Minguijon ESilva JTfalseRezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real-World Clinical Practice.<h4>Background</h4>Echinocandins are the first-line treatment for invasive candidiasis. Rezafungin is a novel echinocandin with improved pharmacokinetic properties that allow for once-weekly intravenous administration, offering potential advantages in complex clinical settings.<h4>Objectives</h4>We aimed to describe our real-world experience with rezafungin for the treatment of invasive fungal disease (IFD).<h4>Patients</h4>A retrospective analysis of consecutive patients treated with rezafungin for proven IFD at our center between September 2022 and December 2025 was conducted.<h4>Results</h4>We included 13 patients (mean age: 59.4 ± 17.8 years). Main predisposing conditions included immunosuppression (53.8% [solid organ transplantation in 30.8%]), solid cancer (30.8%) and recent surgical2026-01-01T00:00:00Z2026 Feb2026-07-16T15:12:27.16Z2026-07-09T11:04:10.205ZS-EPMC129225724171844610.1111/myc.70163